FDA Approves Teva's New Schizophrenia Drug Weltruza
Translated & summarized from NEWSru Israel by baba
The U.S. FDA has approved Teva Pharmaceuticals' new monthly subcutaneous schizophrenia medication, Weltruza, which offers improved patient convenience over existing treatments. Clinical trials showed significant symptom improvement and a favorable safety profile. Teva projects peak sales of $1.5 to $2 billion, and its stock rose 5.7% following the announcement.
The story in 6 lines · by baba
- The FDA approved Teva's new monthly subcutaneous schizophrenia drug, Weltruza.
- Weltruza offers improved patient convenience by eliminating loading doses and post-injection observation.
- Clinical trials showed significant symptom improvement and a favorable safety profile for Weltruza.
- Teva projects peak annual sales for Weltruza to reach $1.5 billion to $2 billion.
- Teva's stock increased by 5.7% on Wall Street after the FDA approval announcement.
- This is Teva's second long-acting schizophrenia drug approved by the FDA in 2023.
The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceuticals' new drug, Weltruza, for the treatment of schizophrenia in adults. Weltruza is a long-acting injectable medication administered subcutaneously once a month. It offers a significant advantage over existing treatments by not requiring loading doses, additional oral medication, or post-injection observation periods. Current intramuscular olanzapine formulations necessitate a three-hour observation after each injection. Weltruza will be available in three dosages, 318, 425, and 531 mg, and is expected to reach the market within weeks. Teva reported that clinical trials demonstrated overall symptom improvement, a substantial reduction in disease severity, and enhanced personal and social functioning among patients. The drug's safety profile is consistent with existing treatments. Teva anticipates peak annual sales for Weltruza to reach between $1.5 billion and $2 billion. Following the FDA's announcement, Teva's stock price surged 5.7% on Wall Street, closing at $41.47 and boosting the company's market capitalization to $47.8 billion. This approval follows the FDA's green light in April 2023 for another Teva long-acting schizophrenia drug, Uzedy, which is based on risperidone.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Centre 1Right 2Other 7
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
